Expression of indoleamine 2,3-dioxygenase in metastatic pancreatic ductal adenocarcinoma recruits regulatory T cells to avoid immune detection.
about
From bench to bedside a comprehensive review of pancreatic cancer immunotherapy.Genetics and biology of pancreatic ductal adenocarcinomaIDO2 in Immunomodulation and Autoimmune DiseaseNanomedicine and cancer immunotherapy: focus on indoleamine 2,3-dioxygenase inhibitorsSerum metabolomic profiling of prostate cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trialMetabolomic-derived novel cyst fluid biomarkers for pancreatic cysts: glucose and kynurenineStromal reengineering to treat pancreas cancerA biological basis for depression in pancreatic cancer.Immune sculpting of norepinephrine on MHC-I, B7-1, IDO and B7-H1 expression and regulation of proliferation and invasion in pancreatic carcinoma cellsInhibitors of indoleamine 2,3-dioxygenase: a review of novel patented lead compounds.Cyclooxygenase-2 (COX-2) inhibition constrains indoleamine 2,3-dioxygenase 1 (IDO1) activity in acute myeloid leukaemia cells.Elevation of MMP-9 and IDO induced by pancreatic cancer cells mediates natural killer cell dysfunctionUpregulated expression of indoleamine 2, 3-dioxygenase in CHO cells induces apoptosis of competent T cells and increases proportion of Treg cells.Amino acid catabolism: a pivotal regulator of innate and adaptive immunity.Expression and function analysis of indoleamine 2 and 3-dioxygenase in bladder urothelial carcinomaA Novel Multivariate Index for Pancreatic Cancer Detection Based On the Plasma Free Amino Acid ProfileProcess of hepatic metastasis from pancreatic cancer: biology with clinical significance.Pancreatic ductal adenocarcinoma: a review of immunologic aspects.Pancreatic cancer: role of the immune system in cancer progression and vaccine-based immunotherapyIndoleamine 2,3-dioxygenase activity and clinical outcome following induction chemotherapy and concurrent chemoradiation in Stage III non-small cell lung cancer.Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4.Tumoral indoleamine 2, 3-dioxygenase 1 is regulated by monocytes and T lymphocytes collaboration in hepatocellular carcinoma.The paradoxical patterns of expression of indoleamine 2,3-dioxygenase in colon cancer.Manipulation of indoleamine 2,3 dioxygenase; a novel therapeutic target for treatment of diseases.Tumor immunosuppressive environment: effects on tumor-specific and nontumor antigen immune responses.Role of immune cells in pancreatic cancer from bench to clinical application: An updated reviewThe immunoregulatory mechanisms of carcinoma for its survival and developmentPotential targets for pancreatic cancer immunotherapeutics.The dendritic cell-regulatory T lymphocyte crosstalk contributes to tumor-induced toleranceHost indoleamine 2,3-dioxygenase: contribution to systemic acquired tumor tolerance.Genotyping and expression analysis of IDO2 in human pancreatic cancer: a novel, active target.Therapeutic targeting of inflammation and tryptophan metabolism in colon and gastrointestinal cancer.Tumor cell expression of immune inhibitory molecules and tumor-infiltrating lymphocyte count predict cancer-specific survival in pancreatic and ampullary cancer.Immunodeficiency in Pancreatic Adenocarcinoma with Diabetes Revealed by Comparative Genomics.Obstacles Posed by the Tumor Microenvironment to T cell Activity: A Case for Synergistic Therapies.Pharmacotherapeutic Management of Pancreatic Ductal Adenocarcinoma: Current and Emerging Concepts.The pancreatic cancer microenvironment: A true double agent.Altered tryptophan metabolism in human meningioma.Pancreatic cancer: Update on immunotherapies and algenpantucel-L.The status of immunosuppression in patients with stage IIIB or IV non-small-cell lung cancer correlates with the clinical characteristics and response to chemotherapy.
P2860
Q26765123-3B039247-954A-4299-A215-7AE473334720Q26765438-A2ADDC6C-C9F1-4303-B05D-28E6781AB16EQ27006786-0B58A769-9FF8-4B0B-8425-631A660AC386Q28818166-9C94E1B5-315A-455E-93EC-7E52C91090C3Q28820954-16F82D36-E8B2-4A5E-9060-3396867DD08DQ30010622-19B55E24-6B6C-42D8-897A-A9723DBCE7D4Q33827708-742491A6-9659-4ED1-8101-F115C760295CQ33960726-B0A9B14C-4431-41FA-9EAB-35C934592069Q34429197-D0A7AE4F-542D-4B81-AB5D-3E60F7ACD511Q34616168-6AA41DA4-9144-4718-B11D-8A94CD10FA5DQ34655638-7C184AC0-C243-4E15-8181-E5E23087658CQ34873308-D7AA41D2-CAD0-4FD8-A564-D420348D248AQ35248373-520F0CAF-010C-4AE1-A230-38873512D8AFQ35261125-F4F9FC90-B744-489F-86FA-00F7D7B38F0AQ35406476-0EDB6141-492D-4164-9E8F-30DAB929B487Q35680475-B9620EF9-BA49-4162-8C38-922759B42AD7Q35739397-24F33222-F78A-44AA-A033-E524ECCE61DAQ35870682-63DF2A96-5641-4264-9C09-72E397F4B2C9Q35886496-17DDAC02-68DF-48BE-8D96-C0810762A9A4Q36866163-BB617A41-A9A4-4312-BA81-54BBBBEF0C6EQ36973676-07608ACF-B7BA-4811-BB1C-F36976FC87D9Q37046717-45708315-C497-4AE2-A6E2-6772BF1FFD94Q37329058-9F4D7CA8-C463-493A-B6D1-897126F9C103Q37522460-A797EA7E-9CBC-40A1-A1E2-C35663C12B1FQ37598949-04DABAE2-ADEF-45DB-A0C6-75C56526DF49Q37606102-9B1ABAAF-3E5D-4C22-A6D3-097A3DC1E7BCQ37831426-08B9186D-7281-4B01-97A1-18350BF96879Q37861220-961F20FB-DD81-4F0B-8AD0-9B92DB2621ADQ37959968-234B8ADD-C50D-4201-B920-53952561AB1EQ38047057-3BFDABB3-E86E-415A-AED3-E10DD1502EAAQ38531261-201B5D75-D2D7-4376-A88F-8176C1479A7DQ38571347-982C2A28-188A-4287-9A53-3E38CBBFC0CDQ38687867-19DB1D30-5EED-4B66-8A94-F638741AC646Q38690307-96FB707C-5972-43DE-A4C6-B488E7533E28Q39178061-F9B10D29-9ECA-4B58-9031-36C6F7421200Q39204274-F60CBB1C-9861-4559-8493-E37F6F3EBC7EQ39366753-D4390B6A-1703-413C-95BD-1D538B9B46EBQ39544673-6275C597-36D1-4FC8-96F1-66E9261DDF13Q40261599-0AF63D22-F634-49C0-BC15-A1CF6B9A49CAQ41149149-3B639700-5100-4056-A942-A408CFFAD2DF
P2860
Expression of indoleamine 2,3-dioxygenase in metastatic pancreatic ductal adenocarcinoma recruits regulatory T cells to avoid immune detection.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Expression of indoleamine 2,3- ...... lls to avoid immune detection.
@en
Expression of indoleamine 2,3- ...... lls to avoid immune detection.
@nl
type
label
Expression of indoleamine 2,3- ...... lls to avoid immune detection.
@en
Expression of indoleamine 2,3- ...... lls to avoid immune detection.
@nl
prefLabel
Expression of indoleamine 2,3- ...... lls to avoid immune detection.
@en
Expression of indoleamine 2,3- ...... lls to avoid immune detection.
@nl
P2093
P1476
Expression of indoleamine 2,3- ...... lls to avoid immune detection.
@en
P2093
Agnes Witkiewicz
Brandice Durkan
Charles J Yeo
Jonathan R Brody
Joseph Cozzitorto
Shayna L Showalter
Timothy K Williams
P304
849-54; discussion 854-6
P356
10.1016/J.JAMCOLLSURG.2007.12.014
P577
2008-03-04T00:00:00Z